Inclusion Criteria:

• Histologically or cytologically proven HCC or alpha-fetoprotein level > 400 ng/ml together with hypervascular tumor and cirrhosis documented by CT scan or MRI.
• HCC not amenable to curative treatment (resection, transplantation, percutaneous ablation)
• Presence of at least one dimensionally measurable target lesion with largest diameter >= 2 cm.
• No previous chemoembolization, no previous radiotherapy
• Cancer of the Liver Italian Program (CLIP) score < 4
• World Health Organization (WHO) performance status of 2 or less
• Life expectancy >= 3 months.
• Age >= 18 years.
• Adequate hematologic functions (neutrophil count, at least 1500 per cubic millimeter; platelet count, at least 75,000 per cubic millimetre; Hemoglobin, at least 8 g/dl)
• Adequate liver function (bilirubin, not more than 2 times the upper limit of normal); Adequate renal function (serum creatinine, less than 150 micromol per liter)
• Adequate coagulation function
• Written informed consent

Exclusion Criteria:

• Decompensated cirrhosis (Child-Pugh score > 7)
• CLIP score > 4
• Variceal bleeding during the previous 3 months
• Thromboembolic event during the previous 6 months
• Medical condition requiring full dose anticoagulation or anti-platelet drugs
• Abnormal cardiac function with history of ischemic heart disease in the previous 6 months, uncontrolled hypertension, unstable angina, severe cardiac arrhythmia,
• No brain metastasis, No bone metastasis only
• Previous or current malignancies at other sites
• No concomitant antitumor treatment including tamoxifen or somatostatin analogs
• Unstable systemic diseases or active uncontrolled infections.
• Patients (male and female) not using effective contraception if of reproductive potential.